potential cancer risk for Protopic (tacrolimus) and Elidel (pimecrolimus)

April 2005

There's now concern about a potential cancer risk for Protopic (tacrolimus) and Elidel (pimecrolimus).

FDA is adding a black box warning...and will soon require you to give a Medication Guide to patients getting these drugs.

It's NOT known for sure if these drugs increase cancer risk.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscription Options

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Brand names are used for different drugs in different countries
Dyslipidemia Lower starting doses of Crestor are now recommended for Asians and some other patients
Osteoporosis severe bone, joint, or muscle pain while taking Fosamax or Actonel
Infectious Diseases Should patients being treated for sexually transmitted diseases get extra antibiotics for their partner
Infectious Diseases Adolescents will be the target of several new vaccines
new warning that Gabitril can CAUSE seizures in patients who don't have epilepsy
Dermatology potential cancer risk for Protopic (tacrolimus) and Elidel (pimecrolimus)
Dermatology serious side effects with ibuprofen are focusing attention on Stevens-Johnson syndrome
Cardiology aspirin has different effects in women than in men for preventing first heart attacks and strokes
Cardiology whether atenolol should be used for initial treatment of hypertension
Pediatrics renewed warnings about promethazine use in children
Women's Health oral hormone therapy is NOT helpful for urinary incontinence in postmenopausal women
Hematology & Oncology new formulation of paclitaxel called Abraxane
Supplements supplements to PREVENT migraines